Cargando…
P2Y12 blocker monotherapy after percutaneous coronary intervention
For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is mandatory, but leads to more bleeding than sin...
Autores principales: | Verheugt, F. W. A., Damman, P., Damen, S. A. J., Wykrzykowska, J. J., Woelders, E. C. I., van Geuns, R. -J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556441/ https://www.ncbi.nlm.nih.gov/pubmed/34101134 http://dx.doi.org/10.1007/s12471-021-01582-7 |
Ejemplares similares
-
P2Y(12) Inhibitor Monotherapy after Percutaneous Coronary Intervention
por: Zhou, Xuan, et al.
Publicado: (2022) -
The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
por: Luo, Liman, et al.
Publicado: (2019) -
P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020) -
Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions: 2017 revision
por: Everaert, B., et al.
Publicado: (2017) -
P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
por: Sotomi, Yohei, et al.
Publicado: (2023)